Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

Diabetes

Volumn 52, Issue 6, 2003, Pages 1364-1370

  Bajaj, Mandeep ^a   Suraamornkul, Swangjit ^b   Pratipanawatr, Thongchai ^b   Hardies, Lou J ^b   Pratipanawatr, Wilailak ^b   Glass, Leonard ^b   Cersosimo, Eugenio ^b   Miyazaki, Yoshinori ^b   DeFronzo, Ralph A ^b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; PIOGLITAZONE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; FAT CONTENT; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATCH CLAMP; PRIORITY JOURNAL; STEADY STATE;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, LDL; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KINETICS; LIPID METABOLISM; MALE; MIDDLE AGED; SPLANCHNIC CIRCULATION; TEXAS; THIAZOLES; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 0037567697     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.6.1364     Document Type: Article

References (48)

1. DeFronzo RA: Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5:177-269, 1997
2. DeFronzo RA, Ferrannini E, Hendler R, Felig P, Wahren J: Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. Diabetes 32:35-45, 1983
3. Ferrannini E, Wahren J, Felig P, DeFronzo RA: Role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man. Metabolism 29:28-35, 1980
4. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J: Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin dependent diabetes mellitus. J Clin Invest 76:149-155, 1985
5. DeFronzo RA, Ferrannini E, Hendler R, Wahren J, Felig P: Influence of hyperinsulinemia, hyperglycenua, and the route of glucose administration on splanchnic glucose exchange. Proc Natl Acad Sci U S A 75:5173-5177, 1978
6. Adkins BA, Myers SR, Hendrick GK, Williams PE, Stevenson RW, Cherrington AD: Importance of the route of intravenous glucose delivery to hepatic glucose balance in the conscious dog. J Clin Invest 79:557-565, 1987
7. Myers SR, Biggers DW, Neal DW, Cherrington AD: Intraportal glucose delivery enhances the effects of hepatic glucose load on net hepatic glucose uptake in vivo. J Clin Invest 88:158-167, 1991
8. Ferrannini E, Simonson DC, Katz LD, Reichard G, Bevilacqua S, Barrett EJ, Olsson M, DeFronzo RA: The disposal of an oral glucose load in patients with non-insulin dependent diabetes. Metabolism 37:79-85, 1988
9. Ludvik B, Nolan JJ, Roberts A, Baloga J, Joyce M, Bell JM, Olefsky JM: Evidence for decreased splanchnic glucose uptake after oral glucose administration in non-insulin-dependent diabetes mellitus. J Clin Invest 100:2354-2361, 1997
10. Mitrakou A, Kelley D, Venerman T, Jenssen T, Pangburn T, Reilly J, Gerich J: Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 39:1381-1390, 1990
11. Basu A, Basu R, Shah P, Vella A, Johnson CM, Nair KS, Jensen MD, Schwenk WF, Rizza RA: Type 2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: additional evidence for a defect in hepatic glucokinase activity. Diabetes 50:1351-1362, 2001
12. Bajaj M, Berria R, Pratipanawatr T, Kashyap S, Pratipanawatr W, Belfort R, Cusi K, Mandarino L, DeFronzo RA: Free fatty acid-induced peripheral insulin resistance augments splanchnic glucose uptake in healthy humans. Am J Physiol 283:E346-E352, 2002
13. Shah P, Vella A, Basu A, Basu R, Adkins A, Schwenk WF, Johnson CM, Nair KS, Jensen MD, Rizza RA: Effects of free fatty acids and glycerol on splanchnic glucose metabolism and insulin extraction in nondiabetic humans. Diabetes 51:301-310, 2002
14. Bajaj M, Pratipanawatr T, Berria R, Pratipanawatr W, Kashyap S, Cusi K, Mandarino L, DeFronzo RA: Free Fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes. Diabetes 51:3043-3048, 2002
15. Groop LC, Bonadonna RC, Del Prato S, Ratheiser K, Zyck K, DeFronzo RA: Glucose and free fatty acid metabolism in non-insulin-dependant diabetes mellitus: evidence for multiple sites of insulin resistance. J Clin Invest 84:205-213, 1989
16. Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo RA: The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 72:96-107, 1991
17. Reaven GM: The fourth musketeer: from Alexandre Dumas to Claude Bernard. Diabetologia 38:3-13, 1995
18. Banerji MA, Buckley MC, Chaiken RL, Gordon D, Lebovitz HE, Kral JG: Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord 19:846-850, 1995
19. Kawasaki T, Hashimoto N, Kikuchi T, Takahashi H, Uchiyama M: The relationship between fatty liver and hyperinsulinemia in obese Japanese children. J Pediatr Gastroenterol Nutr 24:317-321, 1997
20. Goto T, Onuma T, Takebe K, Kral JG: The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. Int J Obes Relat Metab Disord 19:841-845, 1995
21. Ryysy L, Hakkinen A, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jarvinen H: Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749-758, 2000
22. Wahrenberg H, Lonnqvist F, Arner P: Mechanisms underlying regional differences in lipolysis in human adipose tissue. J Clin Invest 84:458-467, 1989
23. Kelley DE, Mandarino LJ: Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 49:677-683, 2000
24. Spiegelman BM: PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514, 1998
25. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA: Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210-2219, 2001
26. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA: Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710-719, 2001
27. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:2784-2791, 2002
28. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y: Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22:908-912, 1999
29. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802, 2002
30. Ludvik B, Nolan JJ, Roberts A, Baloga J, Joyce M, Bell JM, Olefsky JM: A noninvasive method to measure splanchnic glucose uptake after oral glucose administration. J Clin Invest 95:2232-2238, 1995
31. DeFronzo R, Tobin J, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
32. Bottomley PA: Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 508:333-348, 1987
33. Petersen KF, West AB, Reuben A, Rothman DL, Shulman GI: Noninvasive assessment of hepatic triglyceride content in humans with 13C nuclear magnetic resonance spectroscopy. Hepatology 24:114-117, 1996
34. Steele R: Influence of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 82:420-430, 1959
35. Kuyumjian J, Kalant N: Absorption of an oral glucose load in the dog. Horm Metab Res 18:587-589, 1986
36. Haffner SM, Miettinen H, Stern MP: Insulin secretion and resistance in nondiabetic Mexican Americans and non-Hispanic whites with a parental history of diabetes. J Clin Endocrinol Metab 81:1846-1851, 1996
37. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956, 1995
38. Hallakou S, Doare F, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, Dugail I, Morin J, Auwerx J, Ferre P: Pioglitazone induces in vivo adipocyte differentiation in obese Zucker fa/fa rat. Diabetes 46:1393-1399, 1997
39. Lambe KG, Tugwood JD: A human peroxisome-proliferator-activated receptor-ganuna is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem 239:1-7, 1996
40. Miyazaki Y, Hardies LJ, Wajcberg E, Glass L, Triplitt C, Bajaj M, Cersosimo E, Mandarino LJ, DeFronzo RA: Effect of pioglitazone on liver fat content, abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus (Abstract). Diabetes 51(Suppl. 2):A69, 2002
41. Greenfield M, Kolterman O, Olefsky J, Reaven GM: Mechanism of hypertriglyceridaemia in diabetic patients with fasting hyperglycaemia. Diabetologia 18:441-446, 1980
42. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazer MA, Chatterjee VKK, O'Rahilly S: Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153, 1997
43. Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E, Gavrilova O, Reitman ML: Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 106:1221-1228, 2000
44. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL: A pilot study of thiazolidinedione, troglitazone, in nonalcoholic steato-hepatitis. Am J Gastroenterol 96:519-525, 2001
45. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120:1183-92, 2001
46. Silverman JF, Pories WJ, Caro JF: Liver pathology in diabetes mellitus and morbid obesity: clinical, pathological, and biochemical considerations. Pathol Annu 24:275-302, 1989
47. Creutzfeldt W, Frerichs H, Sickinger K: Liver diseases and diabetes mellitus. Prog Liver Dis 3:371-407, 1970
48. Nawano M, Oku A, Ueta K, Umebayashi I, Ishirahara T, Arakawa K, Saito A, Anai M, Kikuchi M, Asano T: Hyperglycemia contributes insulin resistance in hepatic and adipose tissue but not skeletal muscle of ZDF rats. Am J Physiol 278:E535-E543, 2000